Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rilematovir in infants hospitalized with RSV infection
NCT02593851Phase 1Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2015
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 1, randomised, double-blind trial of rilematovir in respiratory syncytial virus infection (RSV) (16 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Plasma Concentration, Trough Plasma Concentration and 4 more. Started Dec 2015; status: terminated.
02
Drugs
rilematovir
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT02593851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02593851.